On November 23, the "CSC2019 & CSPC CSPC Daxining® drone dalone listing meeting" was grandly held at Zhengzhou International Convention and Exhibition Center. Professor Ma Changsheng of Beijing Anzhen Hospital, Capital Medical University, Professor Yang Jiefu of Beijing Hospital, Professor Wu Shulin of Guangdong Provincial People's Hospital, Professor Dong Jianzeng of the First Affiliated Hospital of Zhengzhou University, Professor Wang Zulu of Northern General Hospital of the People's Liberation Army, Professor Zhou Shenghua of Second Xiangya Hospital of Central South University Professor Yan Ji, First Affiliated Hospital of University of Science and Technology of China, Professor Yang Xinchun, Beijing Chaoyang Hospital, Capital Medical University, Professor Liu Shaowen, First People's Hospital Affiliated to Shanghai Jiaotong University, Professor Li Guangping, Second Hospital of Tianjin Medical University, Professor Jiang Hong, People's Hospital of Wuhan University, The 13 domestic authoritative experts from Professor Qi Xiaoyong of Hebei Provincial People's Hospital and Professor Bu Peili of Qilu Hospital of Shandong University have witnessed the heavy launch of dronedarone hydrochloride, the first listed drug in China.
During the meeting, Mr. Wang Zhenguo, the CEO of CSPC, first thanked the Chinese Medical Association Cardiovascular Branch for the opportunity for cooperation, and briefed the conference on CSPC's rich cardiovascular products and key layout in the cardiovascular field. The introduction finally expressed the desire of CSPC and the Cardiovascular Branch of the Chinese Medical Association to continue to strengthen cooperation and exchanges.
Professor Ma Changsheng, Chairman-in-Chief of Cardiovascular Diseases Branch of Chinese Medical Association, first congratulated CSPC's new product Daxinning® dronedarone hydrochloride on its grand launch and fully affirmed and praised CSPC's long-term efforts in the cardiovascular field. And layout. President Ma pointed out that dronedarone hydrochloride produced by CSPC is the first product of this type in China to be marketed, and its listing fills a gap in China that does not have this drug. This is of great significance for improving the accessibility of drugs. The introduction of Daxining® will reduce the risk of atrial fibrillation (AF) hospitalization for patients with sinus rhythm who have a history of atrial fibrillation. It will also become another drug choice for patients with paroxysmal or persistent atrial fibrillation to maintain sinus rhythm.
Professor Yang Xinchun, member of the Standing Committee of the Cardiology Division of the Chinese Medical Association, made a special sharing on the choice of drugs for rhythmic control and ventricular rate control of atrial fibrillation. Professor Yang pointed out that for patients with paroxysmal or persistent AF, rhythm control is more preferred, and the choice of specific drugs should be based on the patient's underlying disease and cardiac function status. For long-term rhythm control, the safety of antiarrhythmic drugs determines whether it is the first choice. The advent of the new class III antiarrhythmic drug dronedarone hydrochloride tablets of CSPC will provide a new drug option for clinical use.
In addition, Professor Wang Zulu, member of the Cardiovascular Branch of the Chinese Medical Association, made a special sharing on the application of dronedarone in the treatment of atrial fibrillation. Professor Wang pointed out that safety should be the primary consideration in the long-term control of sinus rhythm, and dronedarone is a preferred option for maintaining sinus rhythm in patients with paroxysmal or persistent atrial fibrillation with high risk factors (non-heart failure). At the same time, Professor Wang also pointed out that dronedarone is an effective antiarrhythmic drug for the treatment of atrial fibrillation, but as a new clinical drug, more evidence-based is needed to promote a more objective understanding of dronedarone.
Finally, Professor Wu Shulin, member of the Standing Committee of the Chinese Medical Association Cardiology Branch, summarized the meeting. Professor Wu first affirmed the value of dronedarone in clinical application. Secondly, Professor Wu also expressed his hope that CSPC will continue to cultivate in the cardiovascular field to provide more high-quality and cheap medicines for patients in China, improve the availability of medicines, and benefit more people.